Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ heise-Angebot: Jetzt in der Make 2/26: Pi Zero als Hacking-Tool (Heise) +++ RASPBERRY PI Aktie +3,60%

PFIZER Aktie

 >PFIZER Aktienkurs 
24.61 EUR    -0.2%    (TradegateBSX)
Ask: 24.62 EUR / 1020 Stück
Bid: 24.6 EUR / 1020 Stück
Tagesumsatz: 39453 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
PFIZER Aktie über LYNX handeln
>PFIZER Performance
1 Woche: +4,1%
1 Monat: +5,5%
3 Monate: +15,8%
6 Monate: +6,3%
1 Jahr: +8,3%
laufendes Jahr: +15,8%
>PFIZER Aktie
Name:  PFIZER INC. DL-,05
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US7170811035 / 852009
Symbol/ Ticker:  PFE (Frankfurt) / PFE (NYSE)
Kürzel:  FRA:PFE, ETR:PFE, PFE:GR, NYSE:PFE
Index:  S&P500
Webseite:  https://www.pfizer.com/
Profil:  Pfizer Inc. is a research-based global biopharmaceutical company founded in 1849 and headquartered in New York. It focuses on the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products worldwide, targeti..
>Volltext..
Marktkapitalisierung:  136531.59 Mio. EUR
Unternehmenswert:  182200.16 Mio. EUR
Umsatz:  54107.64 Mio. EUR
EBITDA:  20846.21 Mio. EUR
Nettogewinn:  6696.55 Mio. EUR
Gewinn je Aktie:  1.18 EUR
Schulden:  58289.85 Mio. EUR
Liquide Mittel:  987.41 Mio. EUR
Operativer Cashflow:  10120.49 Mio. EUR
Bargeldquote:  0.37
Umsatzwachstum:  -13.31%
Gewinnwachstum:  -14.88%
Dividende je Aktie:  1.47 EUR
Dividendenrendite:  6.36%
Dividendenschätzung:  6.17%
Div. Historie:  23.01.26 - 0.363694€
07.11.25 - 0.371649€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  PFIZER
Letzte Datenerhebung:  02.04.26
>PFIZER Kennzahlen
Aktien/ Unternehmen:
Aktien: 5686.27 Mio. St.
Frei handelbar: 99.9%
Rückkaufquote: -
Mitarbeiter: 75000
Umsatz/Mitarb.: 0.72 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 1.76%
Bewertung:
KGV: 20.91
KGV lG: 9.36
KUV: 2.5
KBV: 1.86
PEG-Ratio: -
EV/EBITDA: 8.74
Rentabilität:
Bruttomarge: 66.23%
Gewinnmarge: 12.38%
Operative Marge: 27.99%
Managementeffizenz:
Gesamtkaprendite: 3.67%
Eigenkaprendite: 8.87%
 >PFIZER Anleihen 
>PFIZER Peer Group
Gesundheit, Medizin für Bakterielle- & Pilzinfektionen/ Antibiotika, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Onkologie/ Krebs- Behandlung, mRNA- Forschung/ Impfstoffe, Impfstoffentwicklung/ Impfstoffhersteller
 
02.04.26 - 08:25
Pfizer and BioNTech halt U.S. COVID-19 vaccine study after recruitment struggles (Japan Times)
 
The move comes as COVID vaccine ‌makers grapple ‌with pushback from the U.S. administration and weak U.S. demand for the shots....
02.04.26 - 01:24
Pfizer′s RSV Shot to Be Offered to 3 Million More in England (Bloomberg)
 
Pfizer Inc.'s vaccine to protect against a potentially dangerous respiratory infection will be offered to about three million more people in England through the state-run National Health Service....
02.04.26 - 01:00
Why Pfizer (PFE) Outpaced the Stock Market Today (Zacks)
 
In the most recent trading session, Pfizer (PFE) closed at $28.55, indicating a +1.67% shift from the previous trading day....
01.04.26 - 22:31
Top Pfizer Shareholders (Investopedia)
 
Um den gesamten Artikel unter investopedia.com zu lesen, klicken Sie bitte auf die Überschrift...
01.04.26 - 21:30
Pfizer Wins COVID-19 Vaccine Lawsuits Against Poland and Romania, Awarded USD2.2 Billion in Compensation (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
01.04.26 - 20:51
Pfizer, BioNTech Hit Pause On COVID Shot Trial As Enrollment Falls Flat (Benzinga)
 
Pfizer & BioNTech halt recruitment for a major U.S. COVID vaccine trial for adults 50–64 due to low enrollment. Read the latest updates. Importance Rank:  1 read more...
01.04.26 - 18:27
Exclusive-Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles (Reuters EN)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
01.04.26 - 18:18
Pfizer, BioNTech end U.S. COVID vaccine trial over low enrollments; Reuters (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
01.04.26 - 17:45
Belgian court orders Poland, Romania to accept $2.2B of Pfizer COVID shots (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
01.04.26 - 17:36
Pfizer Wins €1.9 Billion Covid Vaccine Case With Poland, Romania (Bloomberg)
 
Poland and Romania have been ordered by a Belgian court to pay Pfizer Inc. €1.9 billion ($2.2 billion) for Covid-19 vaccines the two countries refused to take delivery of during the pandemic, handing a win to the drug maker's efforts to enforce the contract....
01.04.26 - 11:18
Shionogi completes purchase of Pfizer stake in GSK′s ViiV Healthcare (Alliance)
 
GSK PLC and Shionogi & Co Ltd on Wednesday said the replacement of Pfizer Inc's stake in the ViiV Healthcare Ltd joint...
01.04.26 - 09:01
GSK Announces Completion Of Pfizer′s Exit Of Its Investment In ViiV Healthcare (AFX)
 
NEW YORK CITY (dpa-AFX) - GSK plc (GSK, GSK.L), and Shionogi & Co. announced the completion of the transaction for the 11.7% economic interest in ViiV Healthcare previously held by Pfizer (PFE) to......
31.03.26 - 20:42
Pfizer is said to close South San Francisco research site (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.03.26 - 23:00
Results: 3SBio Full-Year Net Profit RMB8.482 Billion, Up 306%; Final Dividend HKD0.25 (AAStocks)
 
3SBio (01530.HK) announced its 2025 annual results, reporting revenue of RMB17.696 billion, up 94.3% year-on-year, primarily due to licensing revenue from a breakthrough PD-1/VEGF bispecific antibody 707 licensing deal with Pfizer. The company recorded a net profit of RMB8.482 billion, a growth of 305.8%, with an EPS of RMB3.51.......
30.03.26 - 17:24
How Pfizer Makes Money (Investopedia)
 
Pfizer's Biopharma segment contributes most to company revenues...
30.03.26 - 16:45
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know (Zacks)
 
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock....
30.03.26 - 02:48
Prediction: Buying Pfizer Stock Today Could Set You Up for Life (Fool)
 
Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out....
27.03.26 - 00:00
Why the Market Dipped But Pfizer (PFE) Gained Today (Zacks)
 
In the closing of the recent trading day, Pfizer (PFE) stood at $27.57, denoting a +1.06% move from the preceding trading day....
26.03.26 - 15:54
AI-powered Benefits Platform Origin Raises $30 Million Series A+, Bringing Total Funding to Over $50 Million to Tackle the Growing Inefficiency of Global Benefits Spend (Business Wire)
 
New funding will accelerate Origin's Enterprise Benefits Intelligence platform - which was co-created with multinational organisations including Pfizer, Comcast and BP “It's a problem the benefits industry has been trying to solve for 15 years”, says Origin CEO Chris Bruce, “which is only possible thanks to AI.”LONDON--(BUSINESS WIRE)--Origin, the AI native platform reshaping how global organisations manage employee benefits, today announced a $30 million Series A+ funding round. This brings the company's total funding to over $50 million within twelve months. Origin helps organisations to manage one of the largest, least visible areas of workforce spend - global benefits. Its platform identifies inefficiencies, streamlines benefits operations and improves employee experience at scale. The Series A+ is led by Notion Capital, which also participated in Origin's Series A round. Felix Capital, which led the Series A round, Acadian Ventures, and all existing investors are participating in the Seri...
26.03.26 - 13:00
Income Investors Face a Hard Truth About Pfizer’s Payout Safety (24/7 Wall St.)
 
Pfizer (NYSE: PFE) is one of the most widely held dividend stocks among retirement investors. The stock currently yields 6.3%, well above most fixed-income alternatives. But a high yield can be a warning sign, and right now Pfizer's payout mechanics deserve a hard look. Dividend Snapshot Metric Value Annual Dividend $1.72/share Dividend Yield 6.3% Quarterly ... Income Investors Face a Hard Truth About Pfizer's Payout Safety The post Income Investors Face a Hard Truth About Pfizer's Payout Safety appeared first on 24/7 Wall St.....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Don′t marry, be happy. - Hera Lind
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!